Biotech entity
ANKTIVA is most often covered alongside ImmunityBio, which appears in 2 of these 2 stories. The 35-day window averages about 0.4 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.4 for the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ANKTIVA is most often covered alongside ImmunityBio, which appears in 2 of these 2 stories. The 35-day window averages about 0.4 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.4 for the same window. Their average consequence score of 7 runs above the beat's 6.1 for that window. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. This profile follows 2 Biotech stories mentioning ANKTIVA across the period from February 18, 2026 to March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 452 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ANKTIVA. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Warning
FDA flags misleading claims made by Patrick Soon-Shiong regarding off-label uses of Anktiva.
FDA Approval
Anktiva is approved for BCG-unresponsive NMIBC in combination with BCG.
Initial Rejection
FDA issues a Complete Response Letter (CRL) for Anktiva due to manufacturing deficiencies.
The FDA has issued a formal warning to Dr. Patrick Soon-Shiong, the billionaire founder of ImmunityBio, regarding misleading statements made about the company’s bladder cancer therapy, Anktiva. The regulator flagged claims made during a podcast that suggested the drug could treat a broader range of cancers than its current approval allows.
ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Source: The Motley Fool · AOL.com
ANKTIVA is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
